



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/633,771	08/04/2003	Eric Vivier	A33131-PCT-USA-A	6493
21003	7590	09/26/2005	EXAMINER	
BAKER & BOTTS 30 ROCKEFELLER PLAZA NEW YORK, NY 10112			SISSON, BRADLEY L	
			ART UNIT	PAPER NUMBER
			1634	
DATE MAILED: 09/26/2005				

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 10/633,771	Applicant(s) VIVIER ET AL.	
	Examiner Bradley L. Sisson	Art Unit 1634	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-23 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 1-3 is/are rejected.
- 7) ☒ Claim(s) 4-23 is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. ____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|--|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date ____ | 6) <input type="checkbox"/> Other: ____ |



DETAILED ACTION

Claim Objections

8. Claims 4-23 are objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim cannot depend from another multiply dependent claim. See MPEP § 608.01(n). Accordingly, the claims 4-23 not been further treated on the merits.

Claim Rejections - 35 USC § 112

9. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

10. Claims 1-3 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

11. Claim 1 is rejected as indefinite because the instantly claimed method lacks a final process step that clearly relates back to the preamble. For the method of claim 1, the preamble of the instantly claimed method is drawn to a method of documenting a repertoire of an NKR immunoreceptors, while the final process step is that of the detection of the possible hybrids formed between DNAs or cDNAs and the 3' and 5' oligonucleotide pairs and it is thus unclear as to whether the instantly claimed method is drawn to method of documenting a repertoire of an NKR immunoreceptors, or rather the detection of the possible hybrids formed between DNAs or cDNAs and the 3' and 5' oligonucleotide pairs. Method claim requires a last step or phrase in the last step that states the accomplishments of the goals for the method, which were stated in the

Art Unit: 1634

method's preamble. Claim 1 lack such a last step' and are confusing because the additional method step is not sufficiently set forth. While minute details are not required in method claims, at least the basic steps must be recited in a positive, active fashion. See *Ex parte* Erlich, 3 USPQ2d101 1, p.101 1 (Bd. Pat. Applicant. Int. 1986). It is suggested that an amended claim more clearly describing the intended steps be submitted.

12. Claims 1-3 are rejected over the recitation of the phrases "in particular" on line 7.

Regarding claim 1, the phrase "in particular" renders the claim indefinite because it is unclear whether the limitations) following the phrase are part of the claimed invention. See MPEP j 2173.05(d). The metes and bounds of the claims are vague and indefinite.

13. Claims 1-3 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Regarding claims 1-3, the phrase "capable" on line 15 renders the claim indefinite because it is unclear whether the limitations) following the phrase are part of the claimed invention. See MPEP j 2173.05(d). The metes and bounds of the claims are vague and indefinite. Claims 1-3 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claim 1 is rejected over the recitation of the phrase, "functional counterpart" on line 24. It is not clear whether a biological function is claimed or chemical function is claimed or biochemical function is claimed or all of the above-mentioned functions are claimed. The metes and bounds of the claims are vague and indefinite.

14. Claims 1-3 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as

Art Unit: 1634

the invention. Claim 1 is rejected over the recitation of the phrase, "CCNKR counterpart" on line 20 and "SSNKR receptor counterpart" or "IENKR receptor functional counterpart" on lines 22-24. It is not clear how a pair of oligonucleotides hybridizes to a particular DNA and do not hybridize to the same DNA under a fixed condition. The claim is confusing because the positive and negative statements regarding hybridization is not clearly explained and therefore appears to be conflicting and self-contradictory. The metes and bounds of the claims are vague and indefinite.

15. Claims 1-3 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claim 1 is rejected over the recitation of the phrase, "the use" on line 12 and "the bringing" on line 25. The metes and bounds of the claims are vague and indefinite.

16. Claims 1-3 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claim 1 is rejected over the recitation of the phrase, "approximately" on line 19.

17. In the absence of any specific range of approximation, it is not clear what range of temperatures is mentioned here. The metes and bounds of the claims are vague and indefinite.

18. Claims 1-3 are indefinite and vague because the claims are written in the passive tense. Method claims should recite positive, active process steps, see *Ex parte Erlich* 3 USPQ 2d 1011 (BPAI 1986). This rejection may be overcome by amending the claims to recite the active tense, e.g., "providing at least one pair of oligonucleotides..," "hybridizing said DNA or cDNA populations..," and "detecting hybrids formed.."

19. Claims 1-3 are indefinite because the claims contain information in parentheses, i.e. (20 mM tris-HCl). Parentheticals make the claims indefinite because it is unclear whether the

Art Unit: 1634

information in the parentheses has the same, less, or more weight as the rest of the claim language. In particular, it is unclear as to whether the claims are inclusive of any buffer or require the use of the specific buffer comprising 20 mM tris-HCl, etc. Similarly, claim 3 is indefinite over the recitations of "(or respectively NKR receptor) and "(or respectively NKR receptor counterpart."

Claim Rejections - 35 USC § 102

20. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

21. Bottino et al. teach in vitro method of documenting a repertoire of NICK immunoreceptors comprising the KIR p58 and the KAR p50 target receptors (Abstract and Introduction, Page 18 16), characterized in that it comprises:

a. at least one pair of oligonucleotides, one being designated 3' oligonucleotide and the other 5' oligonucleotide, the 3' and 5' oligonucleotides of the same pair being both capable, under hybridization conditions corresponding to incubation, of hybridizing to the DNA or to the cDNA of a target NKR receptor, or NKR counterpart, but not hybridizing, under the same hybridization condition with the DNA or the cDNA of an NKR receptor counterpart, or respectively of an NKR receptor, functional counterpart of the target receptor (Abstract and Introduction, Page 1816 and MATERIALS AND METHODS Section, Identification of PAX molecule-associated transcript Subsection, Page 1820,

Art Unit: 1634

Column 2, to Page 1 822, column 1 and Figure 8). The property of being capable of hybridization to a DNA or cDNA for 1 min in a buffer (20 mM Tris-HCl, pH 8.4; 50 mM KCl; 2.5 mM MgCl₂) at a temperature of between 50 degree centigrade and 65 degree Centigrade approximately, is inherently present in the primer pairs disclosed by Bottino et al.

b. mixing the DNA or cDNA populations of a biological sample of human origin for which it is desired to document the repertoire of target immunoreceptors with an excess of at least one 3' and 5' oligonucleotide pair according to (1) under conditions favorable to the hybridization of this 3' and 5' oligonucleotide pair with the DNA or cDNAs of the biological sample (MATERIALS AND METHODS Section, Identification of PAX molecule-associated transcript Subsection, Page 1820, Column 2 to Page 1822, column 1 and Figure 8), and c) the detection of the possible hybrids formed between these DNAs or cDNAs and the 3' and 5' oligonucleotide pairs) (MATERIALS AND METHODS Section, Identification of PAX molecule-associated transcript Subsection, Page 1820, Column 2 to Page 1822, column 1 and Figure 8).

22. Bottino et al. teach in vitro method characterized in that at least one of the 3' and 5' oligonucleotide pair hybridizes to the target receptor only, not to the DNA or cDNA of a receptor (Figure 8).

23. Bottino et al. teach in vitro method characterized in that the 5' oligonucleotide of the 3' and 5' oligonucleotide pair used for an NKR target receptor hybridizes to the DNA or to the cDNA of an NKR receptor counterpart (Figure 8).

Art Unit: 1634

24. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

25. Claims 1 -3 are rejected under 35 U.S.C. 102 (a) as being anticipated by Hiby et al.

(Molecular Immunology, (1997), Vol. 34, No. 5, pages 419-430).

26. Hiby et al. teach in vitro method of documenting a repertoire of NKR immunoreceptors comprising the KIR p58 and the IQAR p50 target receptors (Abstract and Table 2) characterized in that it comprises'.

a. at least one pair of oligonucleotides, one being designated 3' oligonucleotide and the other 5' oligonucleotide, the 3' and 5' oligonucleotides of the same pair being both capable, under hybridization conditions corresponding to incubation, of hybridizing to the DNA or to the cDNA of a target NKR receptor, or target NKR counterpart, but not hybridizing, under the same hybridization condition with the DNA or the cDNA of an NKR receptor counterpart, or respectively of an NKR receptor, functional counterpart of the target receptor (Abstract and Table 3 and Page 425, column 1, second and third paragraph). The property of being capable of hybridization to a DNA or cDNA for 1 min in a buffer [20 mM Tris-HCl, pH 8.4; 50 mM KCl; 2.5 mM MgCl₂] at a temperature of between 50 degree Centigrade and 65 degree Centigrade approximately, is inherently present in the primer pairs disclosed by Bottino et al.

b. mixing the DNA or cDNA populations of a biological sample of human origin for which it is desired to document the repertoire of target immunoreceptors with an excess

Art Unit: 1634

of at least one 3' and 5' oligonucleotide pair according to (1) under conditions favorable to the hybridization of this 3' and 5' oligonucleotide pair with the DNA or cDNAs of the biological sample (Abstract and Table 3 and Page 423, column 2, last paragraph to page 425, third paragraph and Figure 2), and

c. the detection of the possible hybrids formed between these DNAs or cDNAs and the 3' and 5' oligonucleotide pair(s) (Abstract and Table 3 and Page 423, column 2, last paragraph to page 425, third paragraph and Figure 2).

27. Hiby et al. teach *in vitro* method characterized in that at least one of the 3' and 5' oligonucleotide pair hybridizes to the target receptor only, not to the DNA or cDNA of a receptor (Page 423, column 2, last paragraph to page 425, third paragraph and Figure 2).

28. Hiby et al. teach *in vitro* method characterized in that the 5' oligonucleotide of the 3' and 5' oligonucleotide pair used for an NKR target receptor hybridizes to the DNA or to the cDNA of an NKR receptor counterpart (Page 423, column 2, last paragraph to page 425, third paragraph and Figure 2).

Conclusion

29. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bradley L. Sisson whose telephone number is (571) 272-0751. The examiner can normally be reached on 6:30 a.m. to 5 p.m., Monday through Thursday.

30. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W. Gary Jones can be reached on (571) 272-0745. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1634

31. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Bradley L. Sisson
Primary Examiner
Art Unit 1634

BLS
19 September 2005